Navigation Links
Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
Date:3/4/2013

requent adverse events (AEs) in STARTVerso™ 4 were nausea (37%), fatigue (33%), diarrhea (27%), headache (23%), and weakness (22%). Serious AEs were reported in 32 patients (10%), including three deaths. To date, 18 patients have discontinued study participation due to AEs. The safety results of this study were comparable to those observed in HCV mono-infected treatment-naive patients in prior faldaprevir clinical studies. No patient on ART experienced a loss of HIV viral suppression during the study period.

In a separate oral presentation at CROI, investigators described the results from three open-label Phase 1 studies in healthy volunteers that evaluated the drug-drug interactions of faldaprevir with the common HIV medications darunavir/ritonavir, efavirenz, or tenofovir. In each of these studies, there was no clinically relevant effect of faldaprevir on the pharmacokinetics of any of the HIV medications studied. However, the respective effects of darunavir/ritonavir and efavirenz on faldaprevir informed the study design of STARTVerso™ 4. Patients already taking darunavir/ritonavir or efavirenz were enrolled into the 120mg and 240mg faldaprevir groups in STARTVerso™ 4, respectively.

These drug-drug interaction findings are part of a comprehensive program to evaluate potential drug interactions of faldaprevir with other medications commonly taken by the diverse patient populations infected with HCV. Most AEs in the drug-drug interaction studies were mild or moderate and all were resolved by the end of the trials. Four healthy volunteers discontinued trial participation due to AEs, including mild or moderate rash, mild elevation in hepatic enzyme levels, or moderate myalgia.

"The interim virologic response rates from STARTVerso™ 4 in HCV/HIV co-infected patients, combined with the drug-drug interaction results of faldaprevir with common HIV medications, are encouraging as we continue toward our goal of developing new HCV
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015  Effective staffing of key ... recognition and success. Research and ... to provide pharmaceutical and biotech marketing managers with ... budget) that are being channeled into marketing operations ... managers can utilize this report to benchmark their ...
(Date:5/22/2015)... 2015 The leading companies in the ... cardiac rhythm management device market dominate their competition, ... St. Jude Medical, Boston Scientific and Asahi Kasei ... segment. The healthcare market research publisher,s report, ... as a base year, providing forecasts for each ...
(Date:5/22/2015)... and KING OF PRUSSIA, Pa. , May ... has awarded CSL Behring its 2015 Corporate Leadership ... to advancing science and improving the care of the bleeding ... , CEO and Managing Director, CSL Limited, during the NHF ... on May 21. "The National Hemophilia Foundation ...
Breaking Medicine Technology:Effective Marketing Services Group Critical for Pharmaceutical Brand Recognition 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 2National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 4
(Date:5/24/2015)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) May 24, ... sees many patients for concerns about hair loss. ... loss, it is clear that there are environmental factors ... of hormone that can contribute. Since they offer a ... aspects of the peri and post-menopausal woman, they can ...
(Date:5/24/2015)... 24, 2015 Scientists with Cardno ChemRisk, ... air quality compliance issues that may have raised the ... Mesothelioma has just posted an article on the research. ... The group found airborne asbestos levels well above OSHA ... 1984 and 2011. , “Asbestos compliance sampling data associated ...
(Date:5/24/2015)... ProPin is a set of self-animating 3D pin markers ... to pin point locations on a map, to indicate prices or ... users to choose from 30 simplistic presets with geometric design elements ... editors can easily manipulate ProPin presets as a whole. Pixel ... , Using ProPin is easy, simply drag a preset into the ...
(Date:5/24/2015)... 24, 2015 ... - The students were selected ... the fourth annual A Day of ... Geneva National in Lake Geneva. , ... High School,         Jonathan Alfonso,         Bridget Keefe, ...
(Date:5/23/2015)... On May 13, Nithyananda Yoga Foundation ... yogic power learned through meditation and initiation at Special ... India. , Yogamaatha, a nine-year-old girl from North Carolina, ... professionals attending the 2015 Business Advocacy Summit at Capitol ... , In a demonstration that lasted three hours, ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:New Analysis Finds Too Many Employers Ignored OSHA Asbestos Guidelines, According to Surviving Mesothelioma 2Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3
... There might be a reason for all that morning sickness ... that the would-be mother will not digest unhealthy foods//. , ... found to be associated with the vomiting in pregnancy, the ... previous studies in 21 countries to arrive at these conclusions. ...
... in the June issue of The American Journal of ... improve their cognitive function// and brain efficiency by making ... eating, physical fitness, and stress reduction into their daily ... diet and exercise can help people maintain their physical ...
... of salaries of doctors participating in the anti-quota stir was likely ... order to do so was issued on the direction of Director ... Gupta, who was asked to explain the reason behind the order ... ,Gupta was asked to relinquish charge as Registrar by the Director ...
... Ltd today said it has received tentative approval by ... 100mg, 150mg and 200mg strengths. // ,This ... in the world given by USFDA, Aurobindo Pharma informed ... now be available for purchase under the President's Emergency ...
... providing Illinois and Chicago with additional financial assistance to ... to combat influenza pandemic. Health officials have been perturbed ... which has also raised concerns of an impending worldwide ... Services Secretary Michael Leavitt said "The funds will build ...
... Mark B. Landon of Ohio State University College of Medicine ... not risky// to attempt vaginal delivery for a woman who ... were published in the journal Obstetrics and Gynecology. But previous ... have had several previous cesarean deliveries to opt for a ...
Cached Medicine News:Health News:Simple Lifestyle Changes May Improve Cognitive Function and Brain Efficiency 2
... a wide range of storage capacities. Delrin ... platform to agitate smoothly, eliminating the need ... squeak. Sturdy, one-piece perforated drawers with non-slip ... your platelets., ,i.Series platelet agitators feature a ...
Platelet agitator....
The "s" series shakers are available in orbital, reciprocating and Blood Bank Platelet versions....
The "s" series shakers are available in orbital, reciprocating and Blood Bank Platelet versions....
Medicine Products: